PRODUCT INFORMATION



Benzydamine (hydrochloride)

Item No. 39808

CAS Registry No.:	132-69-4	
Formal Name:	N,N-dimethyl-3-[[1-(phenylmethyl)-	
	1H-indazol-3-yl]oxy]-1-propanamine,	
	monohydrochloride	
MF:	$C_{19}H_{23}N_3O \bullet HCI$	N +HCI
FW:	345.9	
Purity:	≥95%	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents	the product specifications. Batch specific analytical	results are provided on each certificate of analysis.

Laboratory Procedures

Benzydamine (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the benzydamine (hydrochloride) in water. We do not recommend storing the aqueous solution for more than one day.

Description

Benzydamine is a non-steroidal anti-inflammatory drug (NSAID).¹ It decreases the viability of THP-1 monocytes, Saos-2 osteosarcoma, and HGF-1 gingival cancer cells (IC₅₀s = 59.08, 30.79, and 52.06 μ g/ ml, respectively). Benzydamine (10 μ g/ml) reduces LPS-induced increases in the levels of IL-6 and TNF- α secreted by THP-1 cells. It decreases the levels of prostaglandin E2 (PGE2; Item No. 14010) and PGF1a (Item No. 15010) in unstimulated or IL-1 β - or TNF- α -stimulated primary human gingival fibroblasts when used at a concentration of $1 \,\mu$ M.² Benzydamine (100 mg/kg) reduces hydrochloric acid levels and increases mucin levels in gastric juices isolated from rats.³ It inhibits carrageenan-induced paw edema in rats when administered orally at a dose of 60 mg/kg or applied topically at 3% (w/w).⁴ Formulations containing benzydamine have been used in the treatment of acute sore throat. This product is also available as an analytical reference standard (Item No. 15161).

References

- 1. Kaval, M.E., Cakir, B., Polatli, E., et al. IL-1β, IL-6 and TNF-α expression levels of macrophage cells induced by benzydamine hydrochloride, benzydamine hydrochloride with chitosan, calcium hydroxide and chlorhexidine medicaments: An ELISA study. Dent. Mater. J. 41(4), 545-551 (2022).
- 2. Modéer, T. and Yucel-Lindberg, T. Benzydamine reduces prostaglandin production in human gingival fibroblasts challenged with interleukin-1 β or tumor necrosis factor α . Acta Odontol. Scand. 57(1), 40-45 (1999).
- 3. Catanese, B., Lisciani, R., and Silvestrini, B. Effects of ulcerogenic and antiulcer drugs on gastric secretion in rats. Pharmacol. Res. Commun. 2(2), 83-90 (1970).
- 4. Lisciani, R., Barcellona, P.S., and Silvestrini, B. Researches on the topical activity of benzydamine. Eur. J. Pharmacol. 3(2), 157-162 (1968).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM